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I. INTRODUCTION AND OVERVIEW
The isolation of the BRCA1 and BRCA2 genes has made it possi-
ble to identify women at increased risk for breast and ovarian cancer,
thereby facilitating informed decisions about surveillance and cancer
prevention options.' Despite these potential medical benefits, the
identification of carriers of deleterious mutations raises numerous
psychological and social challenges for those being tested and for
their family members.2 One of the more pressing and least studied
issues involves the process and outcomes of disclosure of genetic in-
formation within families. The present article addresses family disclo-
sure of information about genetic testing for cancer susceptibility.
Following an overview of the clinical aspects of family disclosure and
the empirical literature on this topic, we present our preliminary data
on the determinants and outcomes of disclosure of BRCA1 and
BRCA2 ("BRCA1/2") genetic information within hereditary breast
cancer families. These data are supplemented with case studies of pa-
tients, highlighting the motivations for and against disclosure and il-
I. See Douglas F. Easton et al., Breast and Ovarian Cancer Incidence in BRCA 1-Mutation
Carriers, 56 AM.J. HUM. GENETICS 265 (1995); Deborah Ford et al., Risks of Cancer in BRCA1-
Mutation Carriers, 343 LANCET 692 (1994); Richard Wooster et al., Identification of the Breast
Cancer Susceptibility Gene BRCA2, 378 NATURE 789, 790 (1995). These studies, the first two of
which are from the Breast Cancer Linkage Consortium, established that the lifetime risks
of breast and ovarian cancer associated with BRCA1 mutations are about 85% and 63%,
respectively, with onset often at a younger age than observed in the general population.
See Easton et al., supra, at 270; Ford et al., at 270. Risks for breast cancer in women with
BRCA2 mutations were found to be comparable to BRCA1, but the ovarian cancer risks
were lower. See Wooster, supra, at 790. Prostate cancer risks appear to be elevated in male
BRCA1 carriers. In addition, colon cancer risks may be elevated in men and women with a
BRCA1 or BRCA2 mutation, and other more rare cancers have been associated with
BRCA2 alterations. See id. Another study found lower risks of breast and ovarian cancer
associated with three common mutations in Ashkenazi Jewish individuals who did not nec-
essarily have a family history of cancer. Jeffery P. Struewing et al., The Risk of Cancer Associ-
ated with Specific Mutations ofBRCA1 and BRCA2 Among AshkenaziJews, 336 NEW ENG. J. MED.
1401, 1401 (1997). The risks were still markedly elevated over the general population. See
id. In addition, prostate cancer risks were elevated, though colon cancer risks were not.
See id; see also generally Wylie Burke et al., Recommendations for Follow-up Care of Individuals
with an Inherited Predisposition to Cancer: II. BRCA1 and BRCA2, 277 JAMA 997 (1997) (dis-
cussing provisional recommendations for early detection and cancer prevention in individ-
uals with a BRCA1 or BRCA2 mutation, including heightened surveillance often
commencing at an early age, and reviewing the data regarding the options for prophylactic
surgery).
2. See Caryn Lerman et al., BRCA1 Testing in Families with Hereditary Breast-Ovarian Can-
cer: A Prospective Study of Patient Decision Making and Outcomes, 275 JAMA 1885, 1889 (1996)
(discussing patients' perception of the benefits, limitations, and risks of testing, which in-
cluded social concerns such as fears about insurance discrimination, and concerns about
emotional adaptation and response of relatives to test results).
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lustrating key counseling issues. Finally, we summarize these data and
discuss the health-related and legal implications.
II. FAMILY DISCLOSURE OF GENETIC INFORMATION IN THE BRCA1
AND BRCA2 GENETIC COUNSELING SETTING
Disclosure of genetic information about cancer susceptibility has
numerous implications for patients, family members, health care prov-
iders, and researchers. In the clinical and research settings, disclosure
of one's mutation status provides a gateway for other family members
to have access to genetic testing research protocols. Typically,
BRCA1/2 testing within a family begins with a woman who has been
diagnosed with breast or ovarian cancer, often at a young age (re-
ferred to as the proband). If a known disease-conferring mutation is
identified, other first-degree relatives such as siblings and children
have a 50% likelihood of also carrying the mutation and having an
increased cancer risk.3 In some families, it is also possible to identify
more distant relatives who are at increased risk such as nieces, neph-
ews, and cousins. With knowledge of the particular mutation carried
by the proband, it becomes possible to offer testing to other family
members for that same mutation.4 However, in the interest of pro-
tecting the confidentiality of the participant, researchers or clinicians
should not approach other family members about their risk status or
about testing. A common process, employed in most clinical research
settings, is to discuss with the proband the implications of her test
result for other family members as well as the attendant personal and
social risks. 5 Probands are then given the option to contact their rela-
tives directly, to have the health care provider contact their relatives,
3. See generally Barbara B. Biesecker et al., Genetic Counseling for Families with Inherited
Susceptibility to Breast and Ovarian Cancer, 269 JAMA 1970 (1993). BRCA1 and BRCA2 alter-
ations are inherited in an autosomal dominant fashion, which means that each child of a
parent with an alteration has a 50% chance of having the same alteration. See generally id.
Male and female offspring are at equal risk of inheriting BRCA1 and BRCA2 mutations.
See generally id.
4. Within high-risk families, the advantage to first testing a woman with breast or ova-
rian cancer diagnosed at an early age is that she is most likely to carry an alteration if one is
present within the family. See Maggie Ponder & Josephine M. Green, BRCA1 Testing: Some
Issues in Moving from Research to Service, 5 PSYCHO-ONCOLOGY 223, 223 (1996). It is possible
to test individuals without knowledge of whether there is a BRCA1 or BRCA2 mutation
present in their family (e.g., if all relatives with breast or ovarian cancer are deceased). Id.
at 228. In such scenarios, a positive result will still yield useful information. However, a
negative test result is not considered to be informative because it is not possible to distin-
guish whether the patient did not inherit a mutation present in her family or whether
there is no detectable BRCA1 or BRCA2 mutation in the family. Id. at 227.
5. See Biesecker et al., supra note 3, at 1972-73. The authors concluded that a protocol
to test for presymptomatic BRCA1 gene mutations should include:
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or not to have any further contact with relatives.6 Probands are also
provided with written materials to share with their relatives to facili-
tate the discussion.
The genetic counselor is perhaps best situated to facilitate in-
formed decisions about family disclosure by reviewing the potential
benefits and risks with the patient. In deciding whether to disclose a
positive test result, one may consider the potential medical benefits
for other relatives. For example, disclosure of one's own test result
may be required to provide a relative with the opportunity to be tested
for the specific mutation in the family, should she or he decide to do
so.7 As mentioned above, such information may have medical value,
particularly to female family members who may have a significantly
elevated breast and ovarian cancer risk.8 A potential benefit to the
proband is that disclosure of a positive test result may also elicit both
emotional support and instrumental assistance in seeking and ob-
taining information and medical care.9 However, disclosure of ge-
netic test results has potential risks, including loss of privacy,
employment and insurance discrimination, and stigmatization.'" In-
dividual distress and family conflict may also be generated by disclo-
sure of genetic information.1 Despite the importance of family
disclosure, there are limited empirical data available on this topic.
(1) precounseling education and assessment; (2) a multidisciplinary team
with expertise in the screening and management of breast and ovarian cancer,
inheritance, DNA testing, and psychosocial counseling issues of late-onset disor-
ders; and (3) follow-up services for the management of the increased risk for
cancer as well as the residual emotional reactions on behalf of family members.
Id. at 1974; see also Lerman et al., supra note 2, at 1886-87 (BRCA1 counseling protocol).
6. See Biesecker et al., supra note 3, at 1972.
7. See Ponder & Green, supra note 4, at 227.
8. See Easton et al., supra note 1, at 265; Ford et al., supra note 1, at 692; Wooster et al.,
supra note 1, at 789; Struewing et al., supra note 1, at 1401.
9. See Biesecker et al., supra note 3, at 1972 (noting that a majority of family members
opted to share the results of BRCA1 testing with family members in an effort to receive
their support).
10. See Mark A. Rothstein, Genetic Testing: Employability, Insurability, and Health Reform, 17
J. NAT'L CANCER INST. MONOCRAPHs 87 (1995); Paul R. Billings et al., Discrimination as a
Consequence of Genetic Testing, 50 AM. J. HUM. GENETICS 476 (1992).
11. See Robert T. Croyle et al., Psychological Responses to BRCA1 Mutation Testing: Prelimi-
nary Findings, 16 HEALTH PSYCHOL. 63, 67-69 (1997) (demonstrating that female carriers
with no history of cancer or prophylactic surgery had high levels of test-related distress as
measured by standard psychological assessments, but that overall, levels of general distress
were not increased in this group); Henry T. Lynch et al., A Descriptive Study of BRCA1 Test-
ing and Reactions to Disclosure of Test Results, 79 CANCER 2219, 2223, 2225-26 (1997) (contain-
ing anecdotal, qualitative descriptions of patient responses to testing, including sadness
and survivor guilt). But see Lerman et al., supra note 2, at 1890 (finding that a subset of the
BRCA1 carriers described in the Lynch et al. paper did not exhibit increases in depression
and functional impairment when evaluated using standardized quantitative measures).
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The following section provides an overview of published data about
the processes and outcomes of family disclosure in the genetic testing
context.
III. LITERATURE REVIEW ON FAMILY COMMUNICATION REGARDING
GENETIC TESTING
Initial research on family communication about genetic testing
suggests that most individuals will contact family members to obtain
information about their family's medical history before counseling.
Researcher Josephine Green and colleagues found that 78% of wo-
men who were scheduled for a genetic counseling session for inher-
ited breast-ovarian cancer susceptibility communicated with a family
member before their appointment to obtain family history informa-
tion.' 2 Specifically, probands were most likely to contact female rela-
tives (i.e., mothers or sisters) for information about their family
history.'3 Reasons for not contacting relatives who could have pro-
vided medical information about the family included not wanting to
upset the relative with discussions about cancer.' 4 Other reasons for
not contacting relatives included lost communication with relatives
and large age differences between siblings.' 5 This study also found
that 88% of respondents shared their post-counseling summary letter
with at least one relative.' 6
Studies of family communication about other genetic disorders
(e.g., cystic fibrosis) suggest that feedback provided by relatives
through verbal and/or nonverbal communication may motivate or
discourage individuals from undergoing genetic testing.' 7 A study of
cystic fibrosis testing found that a person's perceptions of their sib-
lings' reactions to abortion was a significant predictor of usage of pre-
natal testing for this disorder."8  Specifically, respondents who
perceived that their siblings would approve of aborting an affected
12. SeeJosephine Green et al., Family Communication and Genetic Counseling: The Case of
Hereditary Breast and Ovarian Cancer, 6J. GENETIC COUNSELING 45, 51 (1997).
13. See id. at 51-52.
14. See id. at 52.
15. See id.
16. See id. at 53.
17. See Dorothy C. Wertz et al., Attitudes Toward the Prenatal Diagnosis of Cystic Fibrosis:
Factors in Decision Making Among Affected Families, 50 AM. J. Hum. GENETICS 1077, 1083
(1992). Cystic fibrosis is a potentially lethal genetic disease which results in the production
of abnormally thick mucus which can clog the lungs and cause severe infections. See gener-
ally Francis S. Collins, Cystic Fibrosis: Molecular Biology and Therapeutic Implications, 256 SCI-
ENCE 774 (1992). Carriers of the disease have no symptoms, but carrier parents have a 25%
chance of having an affected child. See id.
18. See Wertz et al., supra note 17, at 1082-83.
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fetus were three times more likely to use prenatal diagnosis.19 In the
BRCA1/2 testing context, probands who had strong positive beliefs
about the benefits of genetic testing were likely to also encourage
other family members to participate in genetic testing.2" These stud-
ies underscore the influence of family disclosure and communication
on decision making about genetic testing.
Although most individuals may disclose their genetic test results
to family members, many are reluctant to provide clinicians and re-
searchers with direct access to these family members. In a survey of
attitudes about BRCA1/2 testing among high-risk women, a majority
(>80%) felt that health care providers should not disclose their test
results to immediate family members without their written consent.21
In a cystic fibrosis screening program, only 54% of probands provided
the research team with contact information for their at-risk relatives. 22
Thus, most genetic testing participants desire to maintain control over
the diffusion of genetic information to relatives. Further, these deci-
sions are typically made without consulting with family members.
Willingness to communicate with family members about genetic
testing and genetic disorders may be influenced by factors such as
gender 23 and cultural background. 24 For example, women appear to
be more likely to discuss genetic testing with their female relatives
(i.e., daughters) than with male relatives (i.e., brothers). 25 This may
be attributable to perceptions that only mothers, sisters, and daugh-
ters are at-risk for cancer. 26 Our own data on BRCA1/2 testing,
presented in the next section, provide further support for gender dif-
ferences in family communication about BRCA1/2 testing.
19. See id. at 1081-82.
20. See Andrea Farkas Patenaude et al., Acceptance of Invitationsfor p53 and BRCA I Predis-
position Testing. Factors Influencing Potential Utilization of Cancer Genetic Testing, 5 PSYCHO-ON-
COLOGY 241, 245 (1996).
21. SeeJudith L. Benkendorf et al., Patients' Attitudes About Autonomy and Confidentiality
in Genetic Testing for Breast-Ovarian Cancer Susceptibility, 73 AM. J. MED. GENETICS 296, 298
(1997).
22. SeeJ.R. Sorenson et al., Proband and Parent Assistance in Identifying Relatives for Cystic
Fibrosis Carrier Testing, 63 AM. J. MED. GENETICS 419, 421 (1996).
23. See Martin Richards, Families, Kinship, and Genetics, in THE TROUBLED HELIX: SOCIAL
AND PSYCHOLOGICAL IMPLICATIONS OF THE NEW HUMAN GENETICS 249, 251 (Theresa
Marteau & Martin Richards eds., 1996).
24. SeeJames C. McCroskey & Virginia P. Richmond, Willingness to Communicate: A Cog-
nitive View, in COMMUNICATION, COGNITION, AND ANXIETY 19, 31-32 (Melanie Booth-Butter-
field ed., 1990).
25. See Ponder & Green, supra note 4, at 229-30.
26. See id. at 230.
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Family communication may also differ among individuals with
different ethnic or cultural backgrounds.2 7 Culture has been de-
scribed as a system that influences behavior and perceptions.2 8 For
example, the culture of many African Americans may generally be
characterized as emphasizing the principle of spirituality and valuing
interconnectedness, uniqueness, positivity, and sharing. 29 The cul-
ture of many European Americans is generally based on individualism
and values the right to choose, honesty, sharing, and communica-
tion.3" Research has shown that patterns of family communication
about BRCA1 testing differ between African American and Caucasian
women." In a recent study, Caucasian women at increased risk for
breast cancer were significantly more likely than African American wo-
men to communicate about genetic testing with a spouse and a par-
ent.32 Specifically, 66% of Caucasian women discussed genetic testing
for hereditary breast cancer with their spouse, and 40% discussed it
with a parent versus about 27% of African American women who dis-
cussed this issue with a spouse or parent.33
IV. PRELIMINARY DATA ON THE DETERMINANTS AND OUTCOMES OF
FAMILY COMMUNICATION ABOUT BRCA1 AND BRCA2
TESTING
A. Research Questions
The published literature described previously provides some ini-
tial insights into the processes and determinants of communication of
genetic information within families. However, it is important to assess
communication processes and outcomes in a systematic manner and
to address several key questions about family communication which
are unanswered at present. Our research on BRCA1/2 testing in he-
reditary breast cancer seeks to fill some gaps in our knowledge about
family communication by addressing the following research questions:
27. See McCroskey & Richmond, supra note 24, at 31.
28. See COLLINS 0. AIRHIHENBUWA, HEALTH AND CULTURE: BEYOND THE WESTERN PARA-
DIGM 3 (1995).
29. See Anita P. Jackson & Susan J. Sears, Implications of an Africentric Worldview in Reduc-
ing Stress for African American Women, 71 J. COUNSELING & DEV. 184, 186 (1992).
30. SeeJudith N. Martin et al., Conversational Improvement Strategies for Interethnic Commu-
nication: African American and European American Perspectives, 61 COMM. MONOGRAPHS 236,
237 (1994).
31. See Chanita Ann Hughes, Genetic Testing for Inherited Breast-Ovarian Cancer Susceptibil-
ity: The Role of Communication and Personality Characteristics, 62, 64-65 (1997) (unpublished
Ph.D. dissertation, Howard University) (on file with the Department of Psychology, How-
ard University).
32. See id. at 65.
33. See id.
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(1) Among carriers and noncarriers of BRCA1/2 mutations, what are
the rates of self-reported disclosure of BRCA1/2 test results to differ-
ent family members?; (2).Are women more likely to disclose their
BRCA1/2 test results than are males?; and (3) What are the psycho-
logical consequences to the proband of disclosing BRCA1/2 test re-
sults to family members? The first two of these questions are
addressed in a family-based study of BRCA1/2 testing, conducted in
collaboration with Dr. Henry Lynch at Creighton University. The
third question is addressed in a clinic-based study conducted at the
Lombardi Cancer Center at Georgetown University Medical Center.
B. Study #1: A Family-Based Study of BRCA1 and BRCA2 Testing
In this prospective cohort study, eligible participants are male
and female members of hereditary breast cancer families who partici-
pated in earlier genetic linkage studies contributing to the isolation of
the BRCA1/2 genes. Consequently, the pedigrees had been com-
pleted as part of the earlier research and the contact information on
all family members was available. Thus, in contrast to most clinic-
based studies, the proband is not placed in the position of providing
contact information for other relatives at the time of study entry.
The current study was conducted on a family by family basis.
First, letters of introduction were mailed to family members to inform
them that the breast cancer susceptibility gene in their family had
been identified and that genetic counseling and testing are now avail-
able. Consenting family members were asked to participate in a base-
line telephone interview to assess demographic characteristics, risk
factors, and psychosocial well-being.- Individuals interested in genetic
counseling and testing had the opportunity to participate in a pre-test
education session; most of these sessions were conducted with the ex-
tended family. Those who elected to receive their BRCA1/2 test re-
sults did so after completing additional written consent forms and
participating in individual genetic counseling. In this study, we are
following mutation carriers, noncarriers, and decliners of BRCA1/2
testing for a one-year period to evaluate the psychosocial and medical
impact of testing. The data on family communication presented here
are based on the one-month follow-up assessment.
The frequencies for self-reported disclosure of BRCA1/2 test re-
sults among 201 carriers and noncarriers of BRCA1/2 mutations are
shown in Figure 1. Overall, rates of disclosure within the first month
following testing were quite high. For example, 81% of carriers dis-
closed their results to a sister and 60% disclosed to a brother. The
rates of disclosure to minor children were surprisingly high, consider-
[VoLE. 1:353
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ing the fact that there are no immediate medical implications for
young children.34 Seventy-seven percent of carriers disclosed to an
adult child, 47% disclosed to a child age fourteen to eighteen and
37% disclosed to a child under age thirteen.
FIGURE 1. FAMILY DISCLOSURE OF BRCA1/2 TEST RESULTS BY CARRIER
STATUS
Sister 8 85 Test Result
8 NoncarrierI
Brother 1 63
60
Spouse 96
90
Child >18 76
[777
titd 14-18 4747
Child <13 1 3537
0 10 20 30 40 50 60 70 80 90 100
% disclosing
With respect to gender differences, self-reported rates of disclo-
sure of test results among eighty-nine male and female mutation carri-
ers are shown in Figure 2. Female carriers were more likely than
males to disclose to a variety of family members. This was especially
true for disclosure to sisters (89% of females versus 56% of males) and
disclosure to children ages fourteen to eighteen (54% of females and
34. But see Ann-Marie Codori et al., Genetic Testing for Cancer in Children: Short-term Psy-
chological Effect, 150 ARCHIVES PEDIATRIC ADOLESCENT MED. 1131 (1996); F.J.M. Grosfeld et
al., Psychological Risks of Genetically Testing Children for a Hereditary Cancer Syndrome, 32 PA-
TIENT EDuc. & COUNSELING 63, 64 (1997). These studies address genetic testing for condi-
tions such as familial adenomatous polyposis, which can be associated with colon cancer in
adolescents, and multiple endocrine neoplasia type 2A, which is associated with a serious
form of thyroid cancer, for which prophylactic surgery in children is a consideration. See
generally Codori et al., supra; Grosfeld et al., supra. In general, both studies concluded that
there may be significant benefits to offering testing to children for predisposition to these
disorders. See generally Codori et al., supra; Grosfeld et al. supra. There are other rare
cancer predisposition syndromes for which it may be appropriate to test children, but the
major reason for testing children is when there is an immediate medical benefit. See The
American Society of Human Genetics Board of Directors and The American College of
Medical Genetics Board of Directors, ASHG/ACMG Report: Points to Consider: Ethical, Legal,
and Psychosocial Implications of Genetic Testing in Children and Adolescents, 57 Am. J. HUM. GE-
NETICS 1233, 1234-36 (1995). In addition, the potential psychological harm must be
weighed against the possible benefits. See id.
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17% of males). One interpretation of these findings is that women
are more comfortable communicating about health issues and dealing
with the emotional sequelae of disclosure of a positive result. From a
social perspective, it is not uncommon for women to take more of the
responsibility for caretaking within the family.35 It is also possible that
the female spouses of the male mutation carriers in this study had
disclosed the results to family members. However, these data are not
available at the present time.
FIGURE 2. DISCLOSURE OF BRCA1/2 TEST RESULTS BY GENDER:
CARRIERS ONLY
Sister
Brother
Spouse
89
56
62
55
89
]91
Genderji e
0Male
Mild >18 78
71
tild 14-18 54
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Mild <13 42
0 10 20 30 40 50 60 70 80 90 100
% disclosing
The results also indicated that the effects of carrier status (i.e.,
BRCA1/2 positive or negative) on disclosure varied by gender. For
example, among males, noncarriers were more likely than carriers to
disclose results to their sisters (78% versus 56%, respectively). By con-
trast, in females, the rate of disclosure to sisters was uniformly high
(88%) and did not differ based on carrier status. The same pattern
emerged for disclosure of BRCA1/2 test results to children. Among
males, 33% of noncarriers and 17% of carriers disclosed their test re-
sults to a child age fourteen to eighteen. Among females, 53% dis-
closed to such a child, and there was no effect of carrier status on
disclosure. Thus, it appears that men may be more comfortable shar-
ing good news than bad news with other family members.
35. See Martin Richards, Families, Kinship, and Genetics, in THE TROUBLED HELIX: SOCIAL
AND PSYCHOLOGICAL IMPLICATIONS OF THE NEW HuMAN GENETICS 249, 258 (Theresa
Marteau & Martin Richards eds., 1996).
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We also found that the likelihood of disclosing positive results
with young children decreased as the education level of the partici-
pant increased. For example, 100% of carriers with less than high
school education disclosed their results to a child age fourteen to
eighteen, compared with 58% of high school and college graduates
and 30% of participants with post-graduate education. To the extent
that education level correlates with knowledge, we might interpret
this to mean that increasing knowledge of the complexities and risks
of disclosure (particularly to children) might dissuade some partici-
pants from disclosing to young children.
C. Study #2: A Clinic-Based Study of BRCA1 and BRCA2 Testing
As a result of their prior participation in genetic studies, the par-
ticipants in the family-based study described above were more aware
of the issues and complexities involved in genetic testing than most
clinical populations. Further, counseling was performed on a family
basis, thereby minimizing the disclosure burden to initial probands.
Therefore, as a point of comparison, we are conducting a prospective
cohort study of the outcomes of BRCA1/2 testing in the clinical set-
ting. The study design is similar to that described above for Study #1,
except that the testing process flows through the initial proband who
is the gateway for providing access to other family members (after the
proband's results are obtained, and if the result is positive). Further,
all counseling and testing is conducted on an individual, rather than
family, basis.
Despite differences in the method of ascertaining families, the
rates of family disclosure in the clinic-based study were very similar to
those for the family-based study. For example, about 81% of carriers
and noncarriers disclosed to sisters and 45% disclosed to brothers.
However, disclosure to children occurred less frequently in this set-
ting and was more common among noncarriers than among carriers.
For example, 40% of noncarriers disclosed their test results to a child
age fourteen to eighteen as compared to 14% of carriers. Further,
21% of noncarriers disclosed to a child under age thirteen as com-
pared to 9% of carriers. This suggests that some genetic testing par-
ticipants may be motivated to disclose negative results for the purpose
of reassuring their children.
With regard to the psychological impact of disclosure on the pro-
band, the outcome appears to depend on the object of the disclosure.
For example, BRCA1/2 carriers (mostly females in this study) who
disclosed their result to their sister exhibited a small decrease in psy-
chological distress, while those who elected not to tell exhibited a
1998]
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small increase. This difference in trend was both statistically and clini-
cally significant. Thus, this finding suggests that sharing a positive test
result with a sister may initially have a positive effect on quality of life.
This may be attributable to the fact that the proband fulfills a per-
ceived responsibility to share information that could be medically sig-
nificant to a close relative, and/or the fact that the proband may
obtain emotional support from the relative.
By contrast, the reverse pattern was observed in the context of
disclosure of positive test results to young children. In this case, pro-
bands who did not disclose their positive test results experienced re-
ductions in distress, while those who did disclose experienced
significant increases. Although preliminary, it is tempting to specu-
late that disclosure to young children may generate, rather than allevi-
ate, psychological distress in carriers. Guilt about transmitting risk to
one's offspring may be exacerbated by such discussions.
V. CASE STUDIES OF FAMILY DISCLOSURE IN THE CLINICAL
RESEARCH SETTING
The concepts and results presented above are elucidated further
by three case studies of the processes and outcomes of family disclo-
sure of BRCA1/2 test results within the clinic-based study described
above. These vignettes are based on actual cases but have been modi-
fied to protect privacy.
A. Case #1: All in Good Time
Ann is a fifty-five year old married Caucasian woman who tested
positive for a BRCA1 alteration. Her medical history is significant for
bilateral breast cancer diagnosed in her forties, for which she under-
went mastectomies. She had her ovaries and uterus removed in her
fifties as a preventive measure. Her mother died from ovarian cancer
in her forties, and one of Ann's daughters had breast cancer at age
thirty. Ann has two other adult daughters and an older brother and
sister, none of whom has a history of cancer. Her siblings have adult
sons and daughters. She also has several maternal cousins who are at
risk for inheriting this alteration.
For Ann, there are few medical implications of this test result.
However,. there are several relatives who may now be tested. If found
to carry this alteration, they would face increased risks for breast and
ovarian cancer in women, and prostate cancer in male relatives.3 6
During the initial pre-test genetic counseling session, Ann expressed
36. See Easton et al., supra note 1, at 265; Ford et al., supra note 1, at 692.
[VOL. 1:353
DISCLOSURE IN GENETIC TESTING
interest in testing to contribute to breast cancer research and also to
gain information for her family, especially her daughters. Prior to ob-
taining her test results, Ann was concerned about the family's reaction
to her results should she test positive, and acknowledged that, as a
parent considering implications to her young adult daughters, she
would harbor potential feelings of sadness, guilt, and even anger if she
tested positive. She had only very limited discussions with her family
about her decision to pursue testing. Of particular concern to her
were the limitations in available screening and prevention options and
how the information might affect her daughters' future childbearing
decisions. Although she recognized the difficulty in communicating
this information with her family, and the potential for significant emo-
tional distress, she felt strongly about the importance of sharing this
information.
When Ann received genetic counseling regarding her positive re-
sults, implications to family members were discussed in addition to
exploring her own reactions and feelings. Of note, she was counseled
that her daughter with breast cancer was very likely to carry this altera-
tion, though Ann was not planning to share the information with her
right away. The two individuals with whom Ann shared her results
most immediately were her minister and her sister. Her sister was in-
terested in testing and their discussions heightened Ann's concerns
about the potential for insurance discrimination, as individuals with-
out a prior history of cancer often have somewhat different worries
about how their insurers will handle this type of "pre-existing" condi-
tion. She also began to explore with her sister issues related to the
dissemination of this information to the rest of the family. Ann's sis-
ter had concerns about her own children learning about their aunt's
test result.
Ann decided to defer discussion about her results with many rela-
tives. For example, she decided not to disclose to her brother because
he was having chronic medical problems. She also decided not to dis-
close to her daughter with breast cancer because she was undergoing
chemotherapy, or to her two other daughters, one of whom was newly
married and one of whom was pregnant. Ann clearly perceived the
latter two events as happy occasions, and believed that news about her
test result could wait until a more appropriate time. Within a year,
she shared the information with all her daughters and her brother.
Ann also contacted by phone some of her cousins with whom she had
a relationship, but was not interested in contacting cousins with whom
she had not seen or spoken to in many years. Eventually, her brother
and sister were tested, but all of her daughters have declined testing at
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the present time. Ann is undergoing counseling now to address her
and her family's experiences with cancer and genetic testing, as well as
other interpersonal issues.
Analysis: Although some individuals are highly motivated to
pursue testing for the sake offamily members and to share test results
with these relatives, established patterns of communication within the
family and the occurrence of other life circumstances are likely to in-
fluence how, when, and with whom test results are discussed.
B. Case #2: Don't Ask, Don't Tell
Deborah is a fifty-four year old married Caucasian woman who
tested positive for a BRCA2 alteration. Her medical history is signifi-
cant for unilateral breast cancer diagnosed at age fifty-two for which
she underwent breast conserving surgery (lumpectomy), followed by
radiation and chemotherapy. Her sister had breast cancer in her mid-
fifties, and there is a very strong family history of cancer on their fa-
ther's side of the family, including breast cancer in two aunts, male
breast cancer, pancreatic cancer, and ovarian cancer. With the excep-
tion of Deborah, all individuals in the family with a diagnosis of can-
cer have died. Deborah has three children in their twenties and
several nieces in their thirties who she thought would probably be in-
terested in genetic testing. She also has numerous cousins who are
also at risk. Prior to learning her test results, Deborah had informed
several relatives that she had obtained genetic testing and alerted
them to the approximate time in which she would receive her results.
Upon learning her results, Deborah expressed "relief' at finally
learning why she developed cancer. Unlike the previous case, these
results could have significant medical implications for herself as well
as her family. Deborah learned that she was at increased risk for de-
veloping another breast cancer (in her affected and opposite breast)
and that she also faced an increased risk of ovarian cancer and possi-
bly pancreatic cancer. 7 She was counseled about options for early
detection (e.g., frequent screenings for breast cancer, blood tests, and
37. See Ford et al., supra note 1, at 693 (describing the risks of contralateral breast
cancers in BRCAI carriers estimated at 64% by age 70); Kenneth Offit, BRCA1: A New
Marker in the Management of Patients with Breast Cancer?, 77 CANCER 599, 600 (1996) (discuss-
ing the possibility that women with BRCA1 and BRCA2 alterations may also be at risk for
ipsilateral breast cancer and the potential impact on management decisions). It is likely
that contralateral breast cancer risks are elevated in BRCA2 carriers as well. See Offit, supra,
at 600; see also Wooster et al., supra note 1, at 790; Struewing et al., supra note 1, at 1401;
Catherine M. Phelan et al., Mutation Analysis of the BRCA2 Gene in 49 Site-Specific Breast
Cancer Families, 13 NATURE GENETICS 120, 121 (1996) (discussing other cancers associated
with BRCA2 alterations including pancreatic cancer).
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ultrasounds for ovarian cancer) and risk reduction (e.g., use of
Tamoxifen, a medication that may reduce the risk of another breast
cancer; removal of her breasts and/or ovaries).s Although Deborah
was concerned about these risks, she opted not to alter her medical
management and believed that the other measures she employed to
stay healthy, such as having a low fat diet and exercising, were suffi-
cient and provided psychological benefits. She felt healthy and
wanted to live with as few reminders of her cancer or her cancer risk
as possible.
With respect to communication of her test results, within the first
several weeks of learning her results, Deborah shared the information
with her husband and a co-worker. She had also dropped hints about
having her results to various family members including her children,
and some of her nieces and cousins. She reported that none of these
individuals inquired further as to what the results were or what the
implications to them might be. Her feeling was that if they did not ask
her directly for the information, she would not share it. She com-
mented that as her children and nieces were young adults, there was
no urgency to share this information, though she was counseled that
women vho have a BRCA2 alteration may face increased risks for
breast and ovarian cancer even in their twenties and thirties. Because
her result did not significantly change her medical management, she
thought it was likely that it would not significantly impact others. She
also feared that if relatives did get testing, they would associate testing
positive with a "death sentence." Although she was aware that these
relatives have a 50% chance of not having the alteration, and that
learning such information could provide a substantial amount of reas-
surance about their cancer risks, she was more focused on the possibil-
ity of their testing positive. Through subsequent discussions with the
counselor, Deborah revealed that at times, she felt somewhat guilty
about "withholding information" from her family. One strategy for
addressing this issue was to role play different language that could be
used to disclose the information and to imagine the relatives' reaction
along with her response.
It has been over a year since Deborah obtained her results, and
no relatives have been notified of this information. Deborah believes
that with time, her feelings about communicating her result may
change, for example, as her children get older or as they consider
having children. If there are changes in Deborah's own history or her
38. See Burke et al., supra note 1, at 997.
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family history of cancer, these events may also affect her feelings about
sharing the information.
Analysis: Individuals' beliefs about the impact of test results for
themselves may affect their perception of how or whether others will
utilize the information, or when they should be notified of the infor-
mation. The health care providers informed Deborah about who is at
risk and offered to facilitate communication with these relatives
about the availability of genetic counseling with the option of testing,
but were respectful of her wishes not to share the information. In
order for individuals to feel comfortable pursuing testing, they must
know that researchers and clinicians will handle the information
responsibly and respect their autonomy and decision process.
C. Case #3: A Family Affair
Margaret is a sixty-five year old married Caucasian woman who
tested positive for a BRCA1 alteration. She had a history of breast
cancer at age forty-five, for which she underwent a mastectomy of her
affected breast and a preventive mastectomy of her opposite breast.
Her family history is notable for two sisters with early onset breast can-
cer, one of whom also had ovarian cancer and was getting treatment
for metastatic ovarian cancer at the time. Margaret also has two sisters
and two brothers who have never had cancer. Their mother was diag-
nosed with breast cancer at age fifty. All of her siblings have adult
children, and she has three daughters. Margaret sought genetic test-
ing. She was initially interested in testing to learn about her risk for
ovarian cancer and also to gain information for her family. Within six
months of learning her results, Margaret opted to have her ovaries
removed-a decision influenced by her sister's battle against ovarian
cancer.
It was clear from the first meeting with Margaret that she as-
sumed a matriarchal role in this family and that the family was very
close. They were also united in family crises, such as the recent death
of Margaret's husband and her sister's illness. Within a few months,
all of her siblings participated in a group pre-test counseling session
(per their request), along with Margaret, and openly shared their
hopes and concerns regarding testing. They received their results in-
dividually, and all reported that they shared their results, regardless of
the outcome, with their children. Some of those children later opted
for testing. Margaret's daughters also opted for group counseling,
and all received testing. Margaret and her siblings were interested in
having the clinical research team assist them in contacting more dis-
tant relatives, such as great aunts and uncles and cousins, to invite
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them to participate in a free genetic counseling clinical research pro-
gram. Some of these individuals did participate and were aware of
Margaret's experiences, and looked to her for information and sup-
port, as did the rest of the family. During follow-up calls, family mem-
bers often shared their feelings about how relatives were coping with
the information. Although subjective, this information allowed the
counselor to gain insight into the type of added support or informa-
tion that could be offered. Margaret's involvement was instrumental
in helping the family benefit from genetic counseling, regardless of
whether or not they chose to get tested or what their result was if they
did get testing.
Analysis: In families that are close-knit, open, and have estab-
lished lines of communication, the transmission of information
about genetic test results may flow with relative ease. Individuals in
these families often rely on each other for information, support, and
advice about medical decision-making. Furthermore, the individual
who initiates testing in such highly motivated families may be central
in these activities. These important roles are often beyond the scope of
what the counselor is able to provide. However, because there is con-
cern that family members may feel somewhat pressured into getting
genetic testing and making certain subsequent decisions, it is incum-
bent upon the counselor to ensure that individuals are aware of the
full spectrum of benefits, limitations, and risks of testing before they
decide whether to get tested. The counselor should also be available to
help them assimilate and cope with the information.
VI. SUMMARY AND IMPLICATIONS
The quantitative and qualitative (case studies) data presented in
this paper have implications, not only in the health care context, but
also in the legal arena. The results of both a family-based and clinic-
based approach to genetic counseling indicate that the vast majority
of genetic counseling participants opted to disclose their test results to
immediate adult family members. Consistent with previous re-
search,39 most of these individuals elected to share the information
themselves, rather than have the information disclosed by counselors
or other health care providers. Complex psychological and medical
issues influenced the decision to disclose, as well as the timing and
mode of disclosure. Clinicians and researchers should be sensitive
also to cultural influences involved in decisions about family
disclosure.
39. See Sorensen et al., supra note 22, at 421.
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Thus, the ability to control the process of disclosure is of great
importance to genetic counseling participants. This raises a variety of
concerns about the disclosure of genetic information by other
sources, such as healthcare providers, insurance companies, or gov-
ernment institutions. From a legal standpoint, the obligations and au-
thority of other sources in disclosure of genetic information is far
from clear. For example, two recent legal cases have rendered differ-
ing opinions about a physician's responsibility to inform relatives
about their risk of developing a genetic disease. The first of these,
Pate v. Threlkel,4° concluded that the physician had a duty to warn the
patient about the genetic nature of the disease and that the patient
could then be expected to warn their family members.41 It was also
stated that disclosure laws would prohibit the physician from warning
other family members.42 The second case, Safer v. Pack,43 reached a
differing conclusion. In this case, it was decided that the physician
did have a duty to inform the family of their risk of developing a ge-
netic disease.44 The second case is obviously at odds with both the
physician's duty to protect patient confidentiality and with the explicit
desires of patients to control the diffusion of their personal genetic
information. While this apparent conflict is far from settled, a recent
analysis suggests that health care providers have a responsibility to at
least inform patients about the implications of their test results to rela-
tives and to encourage (but not advise) patients to share this informa-
tion.45 In addition, the American Society of Human Genetics recently
published a statement maintaining that "genetic information should
be considered as medical information" and further outlining the "ex-
ceptional" circumstances under which a health care provider should
have a discretionary right to disclose genetic information to at-risk
family members.46 It is not clear from this statement whether disclo-
40. 661 So.2d 278 (Fla. 1995).
41. See id. at 282.
42. See id.
43. 677 A.2d 1188 (N.J. Super. Ct. App. Div. 1996), cert. denied, 683 A.2d 1163 (NJ.
1996).
44. See id. at 1192.
45. See Benjamin S. Wilfond et al., Cancer Genetic Susceptibility Testing: Ethical and Policy
Implications for Future Research and Clinical Practice, 10 J.L. MED. & ETHICS (forthcoming
1998).
46. See The American Society of Human Genetics Social Issues Subcommittee on Famil-
ial Disclosure, ASHG Statement: Professional Disclosure of Familial Genetic Information 62 Am. J.
Hum. GENETICS 474, 474 (1998) (discussing that a provider may be permitted to disclose
genetic information "where attempts to encourage disclosure on the part of the patient
have failed; where the harm is highly likely to occur and is serious and foreseeable; where
the at-risk relative(s) is identifiable; and where either the disease is preventable/treatable
or medically accepted standards indicate that early monitoring will reduce the genetic risk"
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sure of BRCA1/2 test results would fall under this purview.47 How-
ever, even with these considerations, the possibility that government
institutions or insurance companies could order and disclose such in-
formation poses even greater threats to patient confidentiality and
well-being.
The data presented herein also show that females are significantly
more likely to disclose genetic information to their relatives, especially
when test results are positive and when the relatives are minor chil-
dren. A particular concern is that such patterns of disclosure may
place females at greater risk in the context of family law disputes.48
For example, it is conceivable that information about a positive muta-
tion status and elevated cancer risk could be used against female mu-
tation carriers in custody disputes or adoption proceedings.49 This
possibility underscores the importance of informing counseling par-
ticipants about a myriad of potential risks associated with family disclo-
sure beyond the medical and psychosocial risks that are typically
addressed.
Although preliminary, other findings from our research suggest
that both disclosure and nondisclosure of positive test results to rela-
tives may result in increased psychological distress for the discloser,
and possibly for the relatives with whom this information is shared,
although data on the latter are not available. Thus, in addition to
informing and counseling patients about the medical and legal risks
noted above, providers may have an obligation to review the poten-
tially adverse psychological effects of family disclosure. It is arguable
that such information should be considered an essential component
of the informed consent process which takes place prior to the provi-
sion of a blood sample for genetic testing and which is reinforced
when results are disclosed.
In the coming years, as genes for several common multiple adult-
onset conditions are identified, many more individuals will have the
opportunity to learn what their future may hold, and will then have to
address the inevitable familial implications of this knowledge. Given
the complexities of the medical decision making and psychological
adjustment associated with genetic testing, it is hoped that an under-
or where "[t]he harm that may result from failure to disclose should outweigh the harm
that may result from disclosure").
47. See id. at 474-83.
48. Telephone Interview with Karen H. Rothenberg, Marjorie Cook Professor of Law
and Director, Law and Health Care Program, University of Maryland School of Law (Janu-
ary 7, 1998).
49. Id.
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standing of the unique determinants and consequences of disclosure
to family members can help clinicians provide better counseling to
these individuals and will encourage legislators to enact and enforce
protections for patient autonomy and confidentiality. This strategy
will help ensure that individuals who decide to pursue genetic testing,
even in the context of its uncertainties, can obtain maximum benefit
while the potential for harm is minimized.
